These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30092671)

  • 1. Progress on norovirus vaccine research: public health considerations and future directions.
    Mattison CP; Cardemil CV; Hall AJ
    Expert Rev Vaccines; 2018 Sep; 17(9):773-784. PubMed ID: 30092671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in human norovirus research and implications for candidate vaccines.
    Cates JE; Vinjé J; Parashar U; Hall AJ
    Expert Rev Vaccines; 2020 Jun; 19(6):539-548. PubMed ID: 32500763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.
    Ramani S; Neill FH; Ferreira J; Treanor JJ; Frey SE; Topham DJ; Goodwin RR; Borkowski A; Baehner F; Mendelman PM; Estes MK; Atmar RL
    Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28249841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norovirus Vaccine: Priorities for Future Research and Development.
    Esposito S; Principi N
    Front Immunol; 2020; 11():1383. PubMed ID: 32733458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the global burden of noroviruses and opportunities for prevention.
    Hall AJ; Glass RI; Parashar UD
    Expert Rev Vaccines; 2016 Aug; 15(8):949-51. PubMed ID: 27142965
    [No Abstract]   [Full Text] [Related]  

  • 7. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
    Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
    J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.
    Aliabadi N; Lopman BA; Parashar UD; Hall AJ
    Expert Rev Vaccines; 2015; 14(9):1241-53. PubMed ID: 26224658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control.
    Lopman BA; Steele D; Kirkwood CD; Parashar UD
    PLoS Med; 2016 Apr; 13(4):e1001999. PubMed ID: 27115709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.
    Richardson C; Bargatze RF; Goodwin R; Mendelman PM
    Expert Rev Vaccines; 2013 Feb; 12(2):155-67. PubMed ID: 23414407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noroviruses: epidemiology, immunity and prospects for prevention.
    Pringle K; Lopman B; Vega E; Vinje J; Parashar UD; Hall AJ
    Future Microbiol; 2015; 10(1):53-67. PubMed ID: 25598337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological Correlates of Protection against a GII.4 Norovirus.
    Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
    Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
    Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norovirus vaccines under development.
    Lucero Y; Vidal R; O'Ryan G M
    Vaccine; 2018 Aug; 36(36):5435-5441. PubMed ID: 28668568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
    Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiologic challenges in norovirus vaccine development.
    Hallowell BD; Parashar UD; Hall AJ
    Hum Vaccin Immunother; 2019; 15(6):1279-1283. PubMed ID: 30481104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.
    Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D;
    Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.